20...1...1...3...5...7...8... 10... 10... 12... 13... 14... 15... 16... 17 90%... 18 1... 20 SARS 36... 21... 23... 23 I
... 25... 26... 29... 31... 32... 33... 36... 37 SARS... 39 17.3%... 40... 41... 43... 44... 44 10... 46... 47... 51... 54... 58 SARS... 59... 60 VS... 62 II
... 68... 70... 71 3... 72... 73... 74... 75... 76... 77... 78... 79... 87... 88... 89... 91... 99... 100... 101... 102... 103... 105... 108 III
... 109...112...113...117...118... 123... 124... 126... 127... 128... 129... 130... 131... 136... 137... 139... 141... 141... 142... 143... 144... 145 IV
... 146... 147 3... 149 VEN TRACOR... 150... 152 10... 153... 154 ( )... 155... 157... 158... 159... 160... 161... 163... 163... 165... 166... 168... 170... 172... 174... 174 V
... 176... 177... 178... 179 16... 180... 182... 183... 185 13 5... 188 I... 190... 192... 194... 194 VI
20 22 20 1
2
10 3
90 11 6 40%% 1994 10 1996 1996 5 4
7 2003 12 30 2004 4 6 8 8 19 66 4870 4 45.1% 33% 31% 56%. 11 5
11 2 6
2001 2003 " " " ". " " " ". " " " " 7
" " " " " " " " 8
( ) 9
30 165 3 1 3 3 110 10
4 37 2 11
3000 19 8 8 12
8 65 ( 28 ) 31 8 ( ) ( ) X 13
60% 28% 12% 16% 40% 20% 4% 14
20 (Donepezil) (Rivastigmin) (Galantamin) 15
30 16
( ) 7 ( ) 17
7 12 5 5 5 15 90% 90% 18
1999 HCCR Hepa Check Hepa Check HCCR 10 / AFP 2 2 50% 20% Hepa Check 551 Hepa Check 2 2 96% 92% Hepa Check 19
1 WHO( ) 2005 1 WHO WHO WHO WHO 20
10 30 SARS 36 8 4 6 SARS SARS 36 6 SARS 36 21 40 210 4 23 4 SARS 21
18 SARS 18 22
25 40 95%. 23
1 24
C- (creactive protein CRP) 70% Tel-Aviv Samuel Melamed 2000 9 1152 C- 25
C- 26% 11% C- 28 26
2% 3% 2000 3000 27
70 30 2003 289 71.6% 2% 15% 28
9 28 5 29
5 4 5 13 15 30
3 4 18% 42% 2 3 (1 5.3 ) 31
1.35 25 4 2/3 1000 1/3 70 25% 10% 32
20 1 1988 7 7 33
7 20 34.9 1.62 59.1 7 30%. 34
4 55.2% 67.1% 35
15 16 25 50 130 29.4%. 8 5 36
11 20 52 6 2 8 4 28 37
1999 38
SARS SARS 39
SARS SARS SARS SARS 17.3% 17.3%. 19 50 40
12 6 8 41
2 2 3 42
1 2 3 4 (WHO) 13 43
16 80% ( )HIV 1089 HIV 947 HIV 23% HIV 40%. 44
45
10% 20% 50% 10% 15% 3 5 50% 10 10 1 46
5 10 1 5 160 33 47
8 (9%) (96%) (83%) (75%) 7 48
26% 4 3 21% 7 9% 16% 17% 6% 10% 2002 34% 19% 49
2002 7% 12% 57% 45% 2002 11% 18% 57% 63% 2002 36% 29% HIV 50
(22%) (20%) (10%) (7%) 2003 8 9 ( ) ( ) 1866 2102 95% 1.75% ( ) 51
52
53
7 31 19 ( ) 54
2000 65% 7 31 9 11 55
1.6 38 39 40 45 75 14 15 20 56
2 5 5 57
58
SARS SARS SARS SARS SARS 5 59
SARS 863 SARS SARS S/D PH SARS 2004 6 1 60
5 4 10 30 10 16 4 31 9 61
VS " " 7 5 (Viagra ) (Glaxo SmithKline GSK) (Avan dia ) 62
2001 9 19 12 63
26 2003 7 2 ( 98805686.0) 3 0.5 10mg 2 8mg 64
22 2001 9 65
WTO 66
12 4 10 1 6 10 ED 600 5000 1700 67
100 80% 25 50% 90% 6 16 68
30 50 16 16 ( ) 7 16 16 2 3 50 100 69
128 50 99 25 75 2003 8000 5 5 4 10 30 10 16 4 31 70
9 B 71
3 8 3 3 3 2 72
73
- - - - Health Day News St.Jude 74
271 4 124 15 23% 3000 20% (HDLcholesterol ) Anne-Sofie Furberg 17 75
Furberg 3 76
7 77
609 40 130 78
100 100 1/2 1/4 2003 10 1000 79
Osteo Plus ( ) GMP ( ) 80
5000 15000 8 81
60 82
2000 8 (David) 4 83
3 10 2003 8 7 1000 84
41 85
156 76 1000 86
400 2003 87
( ) SARS SARS SARS 400 60 8 88
10% 40% 6 B 15 3 89
B 25 1000 1500cc. 5 8 3 23 90
30 8 12 IT 24 2000 91
50 92
93
0.01MHZ 2450MHZ 95% 498 248 94
1998 598 358 96% 99.8%. 1991 95
2000 7 1979 3 20 X 10 96
1. 35 2. 3. 4. X 5. 97
98
D 1 D 1 3 1.7 50% D 99
1.9 2.3 100
7 3 101
ED 2004 3 ( ) (IMHS) ED 5 (EMEA) 1.3 5 2.2 (PEM) 4 3300 INMHS 102
(EMEA) (IMHS) ED 130 110 2300 1.7 103
1(HO 1) 12 HO 1 HO 1 HO 1 HO 1 104
1 HO 1 HO 1 1 HO 1 105
30 10 19.8 106
107
20 4 ( ). 2001 16 K 40 108
33 8 1999 8 1 109
323 32 7 12 110
6 111
1000 1996-112
22 11 11 113
71 18 12 114
7 30 5 / 115
50% 3% 116
( ) 7 19 32 4 2003 11 10 7 19 2400 10% 117
300 8 1 20 ( 118
) 2001 300 119
42 120
121
6 122
95 37 90 35 36 18 123
2600 30 124
10 74 4% 21% GSK 3 GSK 3 125
GSK 3 18 26 126
20 21 60% 70% 8 127
10 10 3 128
(Dana-Farber Cancer Institute) 129
4815 72 12 4 ( ) 130
131
2 132
16 30 20 30 40 133
20 35 80 134
135
-6 136
( ) RAD51 RAD51 137
RAD51 RAD51 RAD51 138
RAD51 2 " " 139
84 1997 5.5% 2002 10.9%. (2001 2005) 140
2005 50% 8 3 2 9 141
10 10 3 142
GMP 1995 143
1997 76% 67%. 8 12 20 300 21 2440 3800 144
3600 1985 1994 12 16 17 20 360 30 161 22 145
20% 10 300 X 6 1909 358 3 146
X 3 45 32 32 22 X 18 X X 79.5% 17.9% X 10 1 X 7 31 147
SARS 8 SARS SARS 5 22 SARS-COV ( ) 36 18 SARS 8 SARS 148
SARS SARS SARS 2 7 90% 99%. SARS 3 149
Ven tracor Ven tracor VentrAssist 150
VentrAssist 6 1/6. 6 Ven trassist VentrAssist VentrAssist 2003 6 7 VentrAssist 3 13 151
36 7 30 5 7 30 7 30 11 18 152
1998 FDA 10 8 1 68 11.7% 2000 513 2000 2001 82 2002 127 2003 154 29 30 153
10 24 4.1 230 5% 75% 154
-3 ( ) 45 7 7 22 100 155
45 7 1988 1991 7 45 156
30 10 74 4% 21% 157
GSK 3 GSK 3 GSK 3 29 10 (1 111 ) 5 H5N1 5 158
29 10 H5N1 5 159
7 2 1 1 160
7 7 28 14 1 2 1990 (Yasuyuki Nakamura) 1980 9300 161
3 1 2 22% 2/3 162
90% 163
3 21 65 164
4 400 60 8 28 165
B ( ) 166
5 6000 10% 167
5% 168
169
7 25 170
(7 15 ) 171
2000 120 1 172
1500 120 600 46% 600 65% 1 10 1 173
90% 4 60 400 174
21 65 175
400 100 300 60 23 20 176
5 8 15 5 14 1 7 35 177
214 9 18 24.1% 0.3% 3316 25 74 II 178
3 9% 3 80% 179
24 15000 16 180
27 16 2004 4 8 6 6 10 4 3 6 26 4 2 180 30 181
20 5 8 15 5 14 1 7 35 182
10 10 1 1 10 ( 1995 ) 2 5 23 183
6 60 184
( ) ( ) 12mg/kg 5mg/kg 7.5mg/kg 1 3 26 185
3 3 455 17 455 186
31.2% 44% 20 5 6 1 5 10 187
A C D 13 5 13 18 18 13 ( ) 7 20 3 188
189
1.3 6 13 I 190
21 16 16 26 C 2002 20 1.1 191
4 25 192
3 58% 193
100 2 50 12 21 2004 194
C (NIH) 195
(FDA) NIH NIH280 / 720 / FDA 200 196
10 1800 12 16 197